Advertisement

Lung

, Volume 196, Issue 5, pp 591–599 | Cite as

Changes in the Burden of Comorbidities in Patients with COPD and Asthma–COPD Overlap According to the GOLD 2017 Recommendations

  • András Bikov
  • Alpár Horváth
  • Gábor Tomisa
  • Liza Bártfai
  • Zoltán Bártfai
COPD

Abstract

Purpose

Comorbidities associated with chronic obstructive pulmonary disease (COPD) affect quality of life and increase mortality. Asthma–COPD overlap (ACO) may express a different profile of comorbidities compared to COPD alone. It is unclear how recent changes in GOLD recommendations affect the profile of comorbidities in COPD and ACO.

Methods

Eight hundred and thirty-four patients with COPD were recruited from 67 Hungarian secondary care outpatient clinics, 469 of them had ACO. Comorbidities were defined by respiratory specialists based on medical history, patient report, and medications. COPD grades were defined according to the old 2016 and the new 2017 GOLD document. Comorbidities were compared along COPD ABCD groups determined by the old and new GOLD.

Results

66 and 72% of the COPD patients in groups C and D (GOLD 2016) were recategorized to groups A and B (GOLD 2017), respectively. There was no difference in the prevalence of disorders along the 2016 GOLD categories except for osteoporosis in ACO (p = 0.01). When the patients were categorized according to the 2017 GOLD criteria, the prevalence of osteoporosis (p = 0.01) was different among the four groups in all COPD patients. Subgroup analysis of non-ACO COPD patients revealed inter-group differences for cardiac arrhythmia (p < 0.01). No alteration was seen in the prevalence of coronary artery disease, hypertension, diabetes, or the total number of comorbidities.

Conclusion

A significant number of patients are recategorized according to the GOLD 2017 criteria. This change only marginally affects the profile of comorbidities; still this needs to be considered when assessing the patients in daily practice.

Keywords

Asthma Asthma–COPD overlap Comorbidities COPD 

Notes

Acknowledgements

The study has been funded by the Chiesi Hungary Ltd. This publication was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences to András Bikov. The funders have no role in statistical analysis or manuscript preparation.

Compliance with Ethical Standards

Conflict of interest

András Bikov received honoraria for data analysis. Zoltán Bártfai have received honoraria for presentation from Chiesi Hungary Ltd. Alpár Horváth and Gábor Tomisa are full time employees of Chiesi Hungary Ltd. The authors report no further conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Global Initiative for Chronic Obstructive Lung Disease (2017) Available from: http://www.goldcopd.org
  2. 2.
    Mannino DM, Thorn D, Swensen A, Holguin F (2008) Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32(4):962–969.  https://doi.org/10.1183/09031936.00012408 CrossRefPubMedGoogle Scholar
  3. 3.
    Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L (2014) The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J 43(4):993–1002.  https://doi.org/10.1183/09031936.00065013 CrossRefPubMedGoogle Scholar
  4. 4.
    Park HJ, Leem AY, Lee SH, Song JH, Park MS, Kim YS, Kim SK, Chang J, Chung KS (2015) Comorbidities in obstructive lung disease in Korea: data from the fourth and fifth Korean National Health and Nutrition Examination Survey. Int J Chronic Obstr Pulm Dis 10:1571–1582.  https://doi.org/10.2147/copd.s85767 CrossRefGoogle Scholar
  5. 5.
    Buch P, Friberg J, Scharling H, Lange P, Prescott E (2003) Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 21(6):1012–1016CrossRefPubMedGoogle Scholar
  6. 6.
    Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F, Parker KO, Scanlon PD, Asirvatham SJ, Brady PA, Rihal CS (2014) Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 114(2):272–277.  https://doi.org/10.1016/j.amjcard.2014.04.030 CrossRefPubMedGoogle Scholar
  7. 7.
    Shibata Y, Watanabe T, Osaka D, Abe S, Inoue S, Tokairin Y, Igarashi A, Yamauchi K, Kimura T, Kishi H, Aida Y, Nunomiya K, Nemoto T, Sato M, Konta T, Kawata S, Kato T, Kayama T, Kubota I (2011) Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. Int J Med Sci 8(7):514–522CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jones PW, Nadeau G, Small M, Adamek L (2014) Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Respir Med 108(1):129–135.  https://doi.org/10.1016/j.rmed.2013.08.015 CrossRefPubMedGoogle Scholar
  9. 9.
    Casanova C, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, Peces-Barba G, Calle-Rubio M, Solanes-Garcia I, Aguero R, de Diego-Damia A, Feu-Collado N, Alfageme I, Irigaray R, Balcells E, Llunell A, Galdiz JB, Marin M, Soler-Cataluna JJ, Lopez-Campos JL, Soriano JB, de-Torres JP (2014) New GOLD classification: longitudinal data on group assignment. Respir Res 15:3.  https://doi.org/10.1186/1465-9921-15-3 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler-Cataluna JJ, van der Molen T, Adamek L, Banik N (2011) Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med 105(1):57–66.  https://doi.org/10.1016/j.rmed.2010.09.004 CrossRefPubMedGoogle Scholar
  11. 11.
    Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J (2010) Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 11:122.  https://doi.org/10.1186/1465-9921-11-122 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Battaglia S, Basile M, Scichilone N, Bellia V (2015) Prevalence of co-morbidities and severity of COPD. COPD 12(4):390–394.  https://doi.org/10.3109/15412555.2014.974734 CrossRefPubMedGoogle Scholar
  13. 13.
    Cabrera Lopez C, Casanova Macario C, Marin Trigo JM, de-Torres JP, Sicilia Torres R, Gonzalez JM, Polverino F, Divo M, Pinto Plata V, Zulueta JJ, Celli B (2018) Comparison of the 2017 and 2015 global initiative for chronic obstructive lung disease reports. Impact on grouping and outcomes. Am J Respir Crit Care Med 197(4):463–469.  https://doi.org/10.1164/rccm.201707-1363OC CrossRefPubMedGoogle Scholar
  14. 14.
    Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jorres RA (2018) The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med 134:79–85.  https://doi.org/10.1016/j.rmed.2017.12.003 CrossRefPubMedGoogle Scholar
  15. 15.
    Global Initiative for Asthma (2017) Global strategy for asthma management and prevention, Available from: http://www.ginasthma.org
  16. 16.
    Pleasants RA, Ohar JA, Croft JB, Liu Y, Kraft M, Mannino DM, Donohue JF, Herrick HL (2014) Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. COPD 11(3):256–266.  https://doi.org/10.3109/15412555.2013.840571 CrossRefPubMedGoogle Scholar
  17. 17.
    Nielsen M, Barnes CB, Ulrik CS (2015) Clinical characteristics of the asthma-COPD overlap syndrome—a systematic review. Int J Chronic Obstr Pulm Dis 10:1443–1454.  https://doi.org/10.2147/copd.s85363 CrossRefGoogle Scholar
  18. 18.
    Agusti A, Hurd S, Jones P, Fabbri LM, Martinez F, Vogelmeier C, Vestbo J, Rodriguez-Roisin R (2013) FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J 42(5):1391–1401.  https://doi.org/10.1183/09031936.00036513 CrossRefPubMedGoogle Scholar
  19. 19.
    Horvath A, Tomisa G, Meszaros A, Barfai L, Bartfai Z (2017) Assessing the characteristics of patients with COPD and asthma-COPD overlap syndrome within the framework of a real-life prospective study. Med Thoracalis 70(1):53–62Google Scholar
  20. 20.
    Tudoric N, Koblizek V, Miravitlles M, Valipour A, Milenkovic B, Barczyk A, Somfay A, Zykov K, Kostov K, Zbozinkova Z, Svoboda M, Sorli J, Krams A, Tkacova R (2017) GOLD 2017 on the way to a phenotypic approach? Analysis from the phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur Respir J.  https://doi.org/10.1183/13993003.02518-2016 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Okazaki R, Watanabe R, Inoue D (2016) Osteoporosis associated with chronic obstructive pulmonary disease. J Bone Metab 23(3):111–120.  https://doi.org/10.11005/jbm.2016.23.3.111 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sakurai-Iesato Y, Kawata N, Tada Y, Iesato K, Matsuura Y, Yahaba M, Suzuki T, Ikari J, Yanagawa N, Kasahara Y, West J, Tatsumi K (2017) The relationship of bone mineral density in men with chronic obstructive pulmonary disease classified according to the global initiative for chronic obstructive lung disease (GOLD) combined chronic obstructive pulmonary disease (COPD) assessment system. Intern Med 56(14):1781–1790.  https://doi.org/10.2169/internalmedicine.56.6910 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Raluy-Callado M, Lambrelli D, MacLachlan S, Khalid JM (2015) Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013. Int J Chronic Obstr Pulm Dis 10:925–937.  https://doi.org/10.2147/copd.s82064 CrossRefGoogle Scholar
  24. 24.
    Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J (2013) Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 42(3):636–646.  https://doi.org/10.1183/09031936.00195212 CrossRefPubMedGoogle Scholar
  25. 25.
    Han MK, Muellerova H, Curran-Everett D, Dransfield MT, Washko GR, Regan EA, Bowler RP, Beaty TH, Hokanson JE, Lynch DA, Jones PW, Anzueto A, Martinez FJ, Crapo JD, Silverman EK, Make BJ (2013) GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 1(1):43–50.  https://doi.org/10.1016/s2213-2600(12)70044-9 CrossRefPubMedGoogle Scholar
  26. 26.
    Westerik JA, Metting EI, van Boven JF, Tiersma W, Kocks JW, Schermer TR (2017) Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res 18(1):31.  https://doi.org/10.1186/s12931-017-0512-2 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Miyazaki M, Nakamura H, Chubachi S, Sasaki M, Haraguchi M, Yoshida S, Tsuduki K, Shirahata T, Takahashi S, Minematsu N, Koh H, Nakamura M, Sakamaki F, Terashima T, Sayama K, Jones PW, Asano K, Betsuyaku T (2014) Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res 15:13.  https://doi.org/10.1186/1465-9921-15-13 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Slats A, Taube C (2016) Asthma and chronic obstructive pulmonary disease overlap: asthmatic chronic obstructive pulmonary disease or chronic obstructive asthma? Ther Adv Respir Dis 10(1):57–71.  https://doi.org/10.1177/1753465815617082 CrossRefPubMedGoogle Scholar
  29. 29.
    Postma DS, Rabe KF (2015) The Asthma-COPD overlap syndrome. N Engl J Med 373(13):1241–1249.  https://doi.org/10.1056/NEJMra1411863 CrossRefPubMedGoogle Scholar
  30. 30.
    Koblizek V, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K, Tudoric N, Kostov K, Zbozinkova Z, Svancara J, Sorli J, Krams A, Miravitlles M, Valipour A (2017) Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J.  https://doi.org/10.1183/13993003.01446-2016 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ekerljung L, Mincheva R, Hagstad S, Bjerg A, Telg G, Stratelis G, Lotvall J (2018) Prevalence, clinical characteristics and morbidity of the Asthma-COPD overlap in a general population sample. J Asthma 55(5):461–469.  https://doi.org/10.1080/02770903.2017.1339799 CrossRefPubMedGoogle Scholar
  32. 32.
    Kumbhare S, Pleasants R, Ohar JA, Strange C (2016) Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. Ann Am Thorac Soc 13(6):803–810.  https://doi.org/10.1513/AnnalsATS.201508-554OC CrossRefPubMedGoogle Scholar
  33. 33.
    Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpelainen M, Kinnula VL, Haahtela T, Laitinen T (2011) Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 48(3):279–285.  https://doi.org/10.3109/02770903.2011.555576 CrossRefPubMedGoogle Scholar
  34. 34.
    Yamauchi Y, Yasunaga H, Matsui H, Hasegawa W, Jo T, Takami K, Fushimi K, Nagase T (2015) Comparison of in-hospital mortality in patients with COPD, asthma and asthma-COPD overlap exacerbations. Respirology 20(6):940–946.  https://doi.org/10.1111/resp.12556 CrossRefPubMedGoogle Scholar
  35. 35.
    van Boven JF, Roman-Rodriguez M, Palmer JF, Toledo-Pons N, Cosio BG, Soriano JB (2016) Comorbidome, pattern, and impact of Asthma-COPD overlap syndrome in real life. Chest 149(4):1011–1020.  https://doi.org/10.1016/j.chest.2015.12.002 CrossRefPubMedGoogle Scholar
  36. 36.
    Andersen H, Lampela P, Nevanlinna A, Saynajakangas O, Keistinen T (2013) High hospital burden in overlap syndrome of asthma and COPD. Clin Respir J 7(4):342–346.  https://doi.org/10.1111/crj.12013 CrossRefPubMedGoogle Scholar
  37. 37.
    Lucke T, Herrera R, Wacker M, Holle R, Biertz F, Nowak D, Huber RM, Sohler S, Vogelmeier C, Ficker JH, Muckter H, Jorres RA (2016) Systematic analysis of self-reported comorbidities in large cohort studies—a novel stepwise approach by evaluation of medication. PLoS One 11(10):e0163408.  https://doi.org/10.1371/journal.pone.0163408 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PulmonologySemmelweis UniversityBudapestHungary
  2. 2.Chiesi Hungary Ltd.BudapestHungary
  3. 3.Department of PulmonologyUniversity of DebrecenDebrecenHungary
  4. 4.Sopron Health CentreSopronHungary
  5. 5.Pereszteg-Pinnye General Practitioner PraxisPeresztegHungary

Personalised recommendations